Health company, ResMed
(ASX:RMD) released their results for the quarter ending 31 March 2019 showing NPAT up 15 per cent with income from operations at $157 million from last quarter's $136 million.
Revenue increased 12 per cent to $662.2 million from the same corresponding period.
This was driven by strong sales of mask and device sales in the US, Canada, Latin America and strong mask sales in Europe and Asia.
ResMed, which belongs to the Zacks Medical has quarterly earnings of $0.89 per share. This compares to earnings of $0.92 per share a year ago.
Shares in ResMed
(ASX:RMD) are trading 7.64 per cent higher at $15.93.
